We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Technique Detects Breaks in Mitochondrial DNA

By LabMedica International staff writers
Posted on 22 Apr 2019
The Splice-Break pipeline is a recently described technique that can detect and quantify mitochondrial DNA (mtDNA) deletions at a high level of resolution.

Deletions in the mitochondrial genome have been implicated in numerous human disorders that often display muscular and/or neurological symptoms due to the high-energy demands of these tissues. More...
Among these "mitochondrial myopathies" are Kearns–Sayre syndrome (KSS), Pearson Syndrome (PS), chronic progressive external ophthalmoplegia (CPEO), Leigh syndrome, and diabetes mellitus.

Investigators at the University of California, Irvine (USA) described a catalogue of 4,489 putative mtDNA deletions, including their frequency and relative read rate. To do this, they employed a combinatorial approach of mitochondria-targeted PCR, next-generation sequencing, bioinformatics, post-hoc filtering, annotation, and validation steps. Their bioinformatics pipeline incorporated MapSplice, an RNA-seq splice junction detection algorithm, to detect and quantify mtDNA deletion breakpoints rather than mRNA splices.

The investigators used their technique to analyze 93 samples from postmortem brain and blood. They found that the 4977-base pairs "common deletion" was neither the most frequent deletion nor the most abundant and that brain contained significantly more deletions than blood.

“Taken together, the pipeline will enable us to look in many brain regions for an accumulation of damage to mitochondria DNA for individuals with various psychiatric symptoms such as depression and psychosis. The ultimate use will be to test other more accessible samples such as blood, saliva, or cerebrospinal fluid from patients to estimate the damage to mitochondria, and quickly identify those individuals who may benefit from drugs and other treatments that give a mitochondria boost and improve psychiatric symptoms,” said senior author Dr. Marquis P. Vawter, a researcher in the department of psychiatry and human behavior at the University of California, Irvine. “This technique allows us to use a single test to measure the accumulation of many types of these deletions and to determine an overall burden of these deletions upon mitochondria functions.”

The study was published in the March 14, 2019, online edition of the journal Nucleic Acids Research.

Related Links:
University of California, Irvine


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Platelet Function Analyzer
PL-12
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
New
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: LVOne uses blood-based biomarkers to detect stroke and identify large vessel occlusion before hospital arrival, providing objective results earlier than traditional assessments. (Photo courtesy of UpFront Diagnostics)

First-of-Its-Kind Rapid Blood Test Gains CE Mark to Support Prehospital Stroke Triage

Rapid stroke identification before hospital arrival is critical because treatment efficacy declines with every minute of delay. However, definitive assessment typically requires hospital-based imaging,... Read more

Molecular Diagnostics

view channel
Image Credit: iStock

Mpox Analysis Reveals Substantial Suspected False Positives Associated with Contamination

Reliable confirmation of mpox can be difficult where multiple rash-causing illnesses co-circulate and laboratory capacity is limited. Although PCR is central to case detection, contamination during specimen... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: Ebola remains a rapidly evolving public health threat with high mortality, underscoring the need for timely diagnosis and decentralized testing closer to patients (Image Credit: Adobe Stock)

Collaboration Targets Blood-Based Ebola Detection Outside Central Laboratories

Co-Diagnostics, Inc. (Salt Lake City, UT, USA) and ReadyGo Diagnostics Ltd. (Bath, UK) have initiated a collaboration to evaluate ReadyGo’s GoCollect with the Co-Dx PCR platform for blood-based molecular... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.